0 533

Cited 21 times in

Effects of statins on dopamine loss and prognosis in Parkinson's disease

DC Field Value Language
dc.contributor.author백경원-
dc.contributor.author손영호-
dc.contributor.author이양현-
dc.contributor.author이필휴-
dc.contributor.author정석종-
dc.contributor.author유한수-
dc.contributor.author이혜선-
dc.date.accessioned2022-02-23T01:34:56Z-
dc.date.available2022-02-23T01:34:56Z-
dc.date.issued2021-10-
dc.identifier.issn0006-8950-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/187781-
dc.description.abstractStatins are more widely used not only for the primary and secondary prevention of cardiovascular disease by blocking cholesterol biosynthesis but also for the potential neuroprotective agents during neurological disorders due to their pleiotropic effects. In this study, we investigate whether the previous use of statins affect baseline nigrostriatal dopamine loss at the time of diagnosis and longitudinal motor and cognitive outcomes in patients with Parkinson's disease. Five hundred drug-naïve patients with Parkinson's disease who underwent dopamine transporter imaging were classified into two groups according to the prior use of statins: patients with and without statin use. Multivariate linear regression was used to determine intergroup differences in dopamine transporter availability. We evaluated the longitudinal changes in levodopa-equivalent dose and dementia conversion between the groups using a linear mixed model and survival analysis, respectively. In addition, mediation analysis was applied to examine the effect of total cholesterol. Patients with Parkinson's disease treated with statins had a lower baseline dopamine transporter availability in the anterior (2.13 ± 0.55 versus 2.37 ± 0.67; P = 0.002), posterior (1.31 ± 0.43 versus 1.49 ± 0.54; P = 0.003) and ventral putamina (1.40 ± 0.39 versus 1.56 ± 0.47; P = 0.002) than that in matched patients with Parkinson's disease without statins. After adjusting for age at symptom onset, sex, disease duration and vascular risk factors, linear regression models showed that a previous treatment with statins remained significantly and independently associated with more severely decreased dopamine transporter availability in the anterior putamen (Beta = -0.140, P = 0.004), posterior putamen (Beta = -0.162, P = 0.001) and ventral putamen (Beta = -0.140, P = 0.004). A linear mixed model revealed that patients with Parkinson's disease being treated with statins had a faster longitudinal increase in levodopa-equivalent dose than those without. A survival analysis showed that the rate of dementia conversion was significantly higher in patients with Parkinson's disease with statins (hazard ratio, 2.019; 95% confidence interval, 1.108-3.678; P = 0.022) than those without. Mediation analyses revealed that the effect of statin treatment on baseline dopamine transporter availability and longitudinal outcome was not mediated by total cholesterol levels. This study suggests that statin use may have a detrimental effect on baseline nigrostriatal dopamine degeneration and long-term outcomes in patients with Parkinson's disease.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfBRAIN-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAged-
dc.subject.MESHCorpus Striatum / diagnostic imaging-
dc.subject.MESHCorpus Striatum / drug effects-
dc.subject.MESHCorpus Striatum / metabolism*-
dc.subject.MESHDopamine / metabolism*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHHydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects-
dc.subject.MESHHydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology-
dc.subject.MESHHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHParkinson Disease / diagnostic imaging-
dc.subject.MESHParkinson Disease / drug therapy*-
dc.subject.MESHParkinson Disease / metabolism*-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.titleEffects of statins on dopamine loss and prognosis in Parkinson's disease-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurology (신경과학교실)-
dc.contributor.googleauthorSeong Ho Jeong-
dc.contributor.googleauthorHye Sun Lee-
dc.contributor.googleauthorSeok Jong Chung-
dc.contributor.googleauthorHan Soo Yoo-
dc.contributor.googleauthorJin Ho Jung-
dc.contributor.googleauthorKyoungwon Baik-
dc.contributor.googleauthorYang Hyun Lee-
dc.contributor.googleauthorYoung H Sohn-
dc.contributor.googleauthorPhil Hyu Lee-
dc.identifier.doi10.1093/brain/awab292-
dc.contributor.localIdA05133-
dc.contributor.localIdA01982-
dc.contributor.localIdA05714-
dc.contributor.localIdA03270-
dc.contributor.localIdA04666-
dc.relation.journalcodeJ00385-
dc.identifier.eissn1460-2156-
dc.identifier.pmid34347020-
dc.identifier.urlhttps://academic.oup.com/brain/article/144/10/3191/6339771?login=true-
dc.subject.keywordParkinson’s disease-
dc.subject.keyworddopamine transporter imaging-
dc.subject.keywordprognosis-
dc.subject.keywordstatin-
dc.contributor.alternativeNameBaik, Kyoungwon-
dc.contributor.affiliatedAuthor백경원-
dc.contributor.affiliatedAuthor손영호-
dc.contributor.affiliatedAuthor이양현-
dc.contributor.affiliatedAuthor이필휴-
dc.contributor.affiliatedAuthor정석종-
dc.citation.volume144-
dc.citation.number10-
dc.citation.startPage3191-
dc.citation.endPage3200-
dc.identifier.bibliographicCitationBRAIN, Vol.144(10) : 3191-3200, 2021-10-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.